
Akouos AKUS
Quarterly report 2022-Q3
added 05-23-2026
Akouos Depreciation & Amortization 2011-2026 | AKUS
Annual Depreciation & Amortization Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.49 M | 1.92 M | 361 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.49 M | 361 K | 1.59 M |
Quarterly Depreciation & Amortization Akouos
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 800 K | 800 K | 748 K | - | 748 K | 500 K | 544 K | - | 500 K | 500 K | 446 K | - | 100 K | 103 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 800 K | 100 K | 526 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings
ARCT
|
3.02 M | $ 7.15 | 1.64 % | $ 196 M | ||
|
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.69 | 4.66 % | $ 198 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Compugen Ltd.
CGEN
|
475 K | $ 2.72 | -2.86 % | $ 254 M | ||
|
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
332 K | $ 0.67 | -6.24 % | $ 30.6 M | ||
|
Esperion Therapeutics
ESPR
|
105 K | $ 3.13 | -0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
4.04 M | $ 31.47 | -3.44 % | $ 847 M | ||
|
Forte Biosciences
FBRX
|
64 K | $ 21.98 | 1.81 % | $ 285 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
2.31 M | $ 0.87 | 1.11 % | $ 145 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
1.74 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
58.8 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
5.37 M | $ 14.63 | -1.68 % | $ 210 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.49 | 2.65 % | $ 5.75 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M |